Affimed (NASDAQ:AFMD) Stock Holdings Lowered by Marshall Wace LLP

Marshall Wace LLP trimmed its holdings in Affimed (NASDAQ:AFMD) by 90.7% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 11,020 shares of the biopharmaceutical company’s stock after selling 107,242 shares during the period. Marshall Wace LLP’s holdings in Affimed were worth $60,000 as of its most recent SEC filing.

Separately, Choreo LLC bought a new stake in Affimed during the 2nd quarter worth about $54,000. Institutional investors own 30.82% of the company’s stock.

Affimed Stock Up 0.3 %

NASDAQ AFMD opened at $3.00 on Monday. The business’s fifty day moving average is $3.82 and its 200-day moving average is $4.89. Affimed has a one year low of $2.23 and a one year high of $8.95. The company has a current ratio of 2.71, a quick ratio of 2.71 and a debt-to-equity ratio of 0.13.

Affimed (NASDAQ:AFMD) last issued its quarterly earnings data on Thursday, September 5th. The biopharmaceutical company reported ($1.09) EPS for the quarter, missing the consensus estimate of ($1.00) by ($0.09). The business had revenue of $0.17 million for the quarter, compared to analysts’ expectations of $1.67 million. Affimed had a negative return on equity of 155.30% and a negative net margin of 2,922.74%. As a group, equities research analysts anticipate that Affimed will post -4.25 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts recently weighed in on the stock. Cantor Fitzgerald reiterated an “overweight” rating on shares of Affimed in a research report on Monday, September 9th. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Affimed in a research note on Friday, September 6th. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $20.00.

About Affimed

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and Europe. Its lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase II clinical trial for hodgkin lymphoma, and completed Phase II clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia.